JP2021520392A - Ａ２ａ受容体アンタゴニストとしてのピラゾロトリアゾロピリミジン誘導体 - Google Patents
Ａ２ａ受容体アンタゴニストとしてのピラゾロトリアゾロピリミジン誘導体 Download PDFInfo
- Publication number
- JP2021520392A JP2021520392A JP2020554834A JP2020554834A JP2021520392A JP 2021520392 A JP2021520392 A JP 2021520392A JP 2020554834 A JP2020554834 A JP 2020554834A JP 2020554834 A JP2020554834 A JP 2020554834A JP 2021520392 A JP2021520392 A JP 2021520392A
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- alkyl
- methyl
- amino
- pyrazolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- YPLCTRRGZGFGAI-CQSZACIVSA-N CNC([C@@H](c1ccccc1)[n]1ncc2c1nc(N)[n]1nc(-c3ccc[o]3)nc21)=O Chemical compound CNC([C@@H](c1ccccc1)[n]1ncc2c1nc(N)[n]1nc(-c3ccc[o]3)nc21)=O YPLCTRRGZGFGAI-CQSZACIVSA-N 0.000 description 1
- YPLCTRRGZGFGAI-AWEZNQCLSA-N CNC([C@H](c1ccccc1)[n]1ncc2c1nc(N)[n]1nc(-c3ccc[o]3)nc21)=O Chemical compound CNC([C@H](c1ccccc1)[n]1ncc2c1nc(N)[n]1nc(-c3ccc[o]3)nc21)=O YPLCTRRGZGFGAI-AWEZNQCLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/082140 | 2018-04-08 | ||
| CN2018082140 | 2018-04-08 | ||
| PCT/CN2019/081785 WO2019196803A1 (en) | 2018-04-08 | 2019-04-08 | Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021520392A true JP2021520392A (ja) | 2021-08-19 |
| JP2021520392A5 JP2021520392A5 (enExample) | 2022-04-07 |
Family
ID=68163465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020554834A Withdrawn JP2021520392A (ja) | 2018-04-08 | 2019-04-08 | Ａ２ａ受容体アンタゴニストとしてのピラゾロトリアゾロピリミジン誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11472811B2 (enExample) |
| EP (1) | EP3774813A4 (enExample) |
| JP (1) | JP2021520392A (enExample) |
| KR (1) | KR20200140849A (enExample) |
| CN (1) | CN112313234B (enExample) |
| AU (1) | AU2019251148A1 (enExample) |
| BR (1) | BR112020020078A2 (enExample) |
| CA (1) | CA3095839A1 (enExample) |
| EA (1) | EA202092036A1 (enExample) |
| IL (1) | IL277744A (enExample) |
| MX (1) | MX2020010618A (enExample) |
| SG (1) | SG11202009706VA (enExample) |
| TW (1) | TW202010500A (enExample) |
| WO (1) | WO2019196803A1 (enExample) |
| ZA (1) | ZA202005772B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200140849A (ko) | 2018-04-08 | 2020-12-16 | 베이진 엘티디 | A2a 수용체 길항제로서의 피라졸로트리아졸로피리미딘 유도체 |
| WO2021191376A1 (en) * | 2020-03-26 | 2021-09-30 | Astrazeneca Ab | Triazolone compounds |
| US12552799B2 (en) | 2020-03-26 | 2026-02-17 | Nxera Pharma Uk Limited | Triazolone compounds |
| WO2022087146A1 (en) | 2020-10-22 | 2022-04-28 | Landos Biopharma, Inc. | Lancl ligands |
| CN113773327B (zh) * | 2021-09-13 | 2022-07-15 | 八叶草健康产业研究院(厦门)有限公司 | 一种吡唑并嘧啶并三唑环类化合物的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1283839E (pt) | 2000-05-26 | 2005-08-31 | Schering Corp | Antagonistas do receptor a2a da adenosina |
| BR0213172A (pt) | 2001-10-08 | 2004-09-14 | Hoffmann La Roche | Amida do ácido 8-amino-[1,2,4]triazolo[1,5-a]piridina-6-carboxìlico |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| ATE461932T1 (de) | 2004-04-21 | 2010-04-15 | Schering Corp | Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors |
| CN103261202B (zh) | 2010-09-24 | 2016-01-20 | 阿迪维纳斯疗法有限公司 | 作为腺苷受体拮抗剂的稠合三环化合物 |
| WO2012135084A1 (en) | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| WO2017136375A1 (en) | 2016-02-05 | 2017-08-10 | Concert Pharmaceuticals, Inc. | Deuterated tozadenant |
| KR20200140849A (ko) | 2018-04-08 | 2020-12-16 | 베이진 엘티디 | A2a 수용체 길항제로서의 피라졸로트리아졸로피리미딘 유도체 |
| CN110742893B (zh) | 2018-07-23 | 2024-04-05 | 百济神州(北京)生物科技有限公司 | A2a受体拮抗剂治疗癌症的方法 |
-
2019
- 2019-04-08 KR KR1020207031434A patent/KR20200140849A/ko not_active Ceased
- 2019-04-08 TW TW108112189A patent/TW202010500A/zh unknown
- 2019-04-08 WO PCT/CN2019/081785 patent/WO2019196803A1/en not_active Ceased
- 2019-04-08 EP EP19785064.7A patent/EP3774813A4/en not_active Withdrawn
- 2019-04-08 AU AU2019251148A patent/AU2019251148A1/en not_active Abandoned
- 2019-04-08 MX MX2020010618A patent/MX2020010618A/es unknown
- 2019-04-08 CN CN201980024422.3A patent/CN112313234B/zh not_active Expired - Fee Related
- 2019-04-08 CA CA3095839A patent/CA3095839A1/en active Pending
- 2019-04-08 EA EA202092036A patent/EA202092036A1/ru unknown
- 2019-04-08 JP JP2020554834A patent/JP2021520392A/ja not_active Withdrawn
- 2019-04-08 US US16/982,681 patent/US11472811B2/en active Active
- 2019-04-08 BR BR112020020078-6A patent/BR112020020078A2/pt not_active IP Right Cessation
- 2019-04-08 SG SG11202009706VA patent/SG11202009706VA/en unknown
-
2020
- 2020-09-17 ZA ZA2020/05772A patent/ZA202005772B/en unknown
- 2020-10-01 IL IL277744A patent/IL277744A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020020078A2 (pt) | 2021-01-05 |
| WO2019196803A1 (en) | 2019-10-17 |
| SG11202009706VA (en) | 2020-10-29 |
| CN112313234A (zh) | 2021-02-02 |
| EA202092036A1 (ru) | 2021-01-28 |
| ZA202005772B (en) | 2022-01-26 |
| US20210198267A1 (en) | 2021-07-01 |
| IL277744A (en) | 2020-11-30 |
| US11472811B2 (en) | 2022-10-18 |
| AU2019251148A1 (en) | 2020-10-22 |
| CA3095839A1 (en) | 2019-10-17 |
| MX2020010618A (es) | 2020-11-12 |
| TW202010500A (zh) | 2020-03-16 |
| CN112313234B (zh) | 2022-04-29 |
| EP3774813A1 (en) | 2021-02-17 |
| EP3774813A4 (en) | 2021-11-17 |
| KR20200140849A (ko) | 2020-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6626449B2 (ja) | ＰＤＥ２阻害剤としての置換［１，２，４］トリアゾロ［１，５−ａ］ピリミジン−７−イル化合物 | |
| JP6475252B2 (ja) | ヘテロアリール置換のニコチンアミド化合物 | |
| JP7577655B2 (ja) | 環状尿素 | |
| US11472811B2 (en) | Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist | |
| US12378224B2 (en) | Heteroaryl compounds and their use as Mer inhibitors | |
| JP6152098B2 (ja) | 治療活性組成物およびそれらの使用方法 | |
| MX2011006575A (es) | Compuestos de aminopiridina y carboxipiridina como inhibidores de la fosfodiesterasa 10. | |
| WO2020186220A1 (en) | Compounds as inhibitors of macrophage migration inhibitory factor | |
| JP7064495B2 (ja) | ＰＩ３Ｋδ阻害剤としてのイミダゾ［１，５－ａ］ピラジン誘導体 | |
| TW202421130A (zh) | 作為pi3k抑制劑的異喹啉酮 | |
| CA3235416A1 (en) | Compounds and their uses as gpr183 inhibitors | |
| JP2025501098A (ja) | ヘテロシクリル化合物 | |
| US20260125346A1 (en) | Isoquinolinone Derivatives and 4H-Quinolizinone Derivatives and Pharmaceutical Compositions Thereof for the Treatment of Disease | |
| JP2025516213A (ja) | サイクリン依存性キナーゼ阻害剤としての置換６－（ピリミジン－４－イル）キノリン化合物 | |
| JP2021506876A (ja) | ＰＤＥ１阻害剤としてのピラゾロ［３，４−ｂ］ピリジン及びイミダゾ［１，５−ｂ］ピリダジン | |
| WO2016184313A1 (zh) | 羟基嘌呤类化合物及其应用 | |
| HK40036174A (en) | Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist | |
| EA050235B1 (ru) | Соединения и их применение в виде ингибиторов gpr183 | |
| HK40012561B (en) | Heteroaryl compounds and their use as mer inhibitors | |
| EA040746B1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-а]ПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kδ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220330 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220330 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20221116 |